Targeting Key Metabolic Enzymes Involved in Lipid and Protein Biosyntheses for Breast Anticancer Therapies.

abstract：:Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

journal_title：Current cancer drug targets

authors： Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:The solute carrier family 7 (SLC7) can be categorically divided into two subfamilies, the L-type amino acid transporters (LATs) including SLC7A5-13, and SLC7A15, and the cationic amino acid transporters (CATs) including SLC7A1-4 and SLC7A14. Members of the CAT family transport predominantly cationic amino ac...

journal_title：Current cancer drug targets

authors： Lu X

更新日期：2019-01-01 00:00:00

abstract：:Lipophilic derivatives of the anticancer drug paclitaxel (PTX) were prepared by means of its conjugation to lipoamino acid (LAA) residues, with the aim of increasing drug accumulation in tumor cells. PTX was linked to the methyl esters of norleucine (C6) or 2-aminodecanoic acid (C10). A succinic acid group was used as...

journal_title：Current cancer drug targets

authors： Pignatello R,Paolino D,Pantò V,Pistară V,Calvagno MG,Russo D,Puglisi G,Fresta M

更新日期：2009-03-01 00:00:00

abstract：:CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors a...

journal_title：Current cancer drug targets

authors： D'Alterio C,Consales C,Polimeno M,Franco R,Cindolo L,Portella L,Cioffi M,Calemma R,Marra L,Claudio L,Perdonà S,Pignata S,Facchini G,Cartenì G,Longo N,Pucci L,Ottaiano A,Costantini S,Castello G,Scala S

更新日期：2010-11-01 00:00:00

abstract：:Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways...

journal_title：Current cancer drug targets

authors： Cai T,Li X,Ding J,Luo W,Li J,Huang C

更新日期：2011-06-01 00:00:00

abstract：:One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, s...

journal_title：Current cancer drug targets

authors： González G,Lage A

更新日期：2007-05-01 00:00:00

abstract：:(5Z,9Z)-11-Phenylundeca-5,9-dienoic acid was stereoselectively synthesized, based on original cross-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran and buta-2,3-dien-1-ylbenzene with EtMgBr in the presence of the Cp2TiCl2 catalyst giving 2,5-dialkylydenemagnesacyclopentane in 86% yield. The acid hyd...

journal_title：Current cancer drug targets

authors： D'yakonov VA,Dzhemileva LU,Makarov AA,Mulyukova AR,Baevd DS,Khusnutdinova EK,Tolstikova TG,Dzhemilev UM

更新日期：2015-01-01 00:00:00

abstract：:Cancer drug therapy is undergoing a major transition from the previous pregenomic cytotoxic era to the new postgenomic era. Future mechanism-based therapeutic agents will increasingly be designed to act on molecular targets that are causally involved in the malignant progression of human cancers. Such agents are predi...

journal_title：Current cancer drug targets

authors： Workman P

更新日期：2001-05-01 00:00:00

abstract：BACKGROUND:MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. METHODS:In this research, we successfully constructed 11-mercaptoundecanoic acid modified go...

journal_title：Current cancer drug targets

authors： Yan LJ,Guo XH,Wang WP,Hu YR,Duan SF,Liu Y,Sun Z,Huang SN,Li HL

更新日期：2019-01-01 00:00:00

abstract：:Copper is a trace element which is tightly regulated in mammals and lower animals. Disruptions of copper homeostasis in humans are rare and they cause serious disorders such as Wilson's disease and Menke's disease. Copper plays an important role in promoting physiological and malignant angiogenesis. Formation of new b...

journal_title：Current cancer drug targets

authors： Goodman VL,Brewer GJ,Merajver SD

更新日期：2005-11-01 00:00:00

abstract：:Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may...

journal_title：Current cancer drug targets

authors： Donkena KV,Yuan H,Young CY

更新日期：2010-06-01 00:00:00

abstract：:Scaffold-based analogs of cinnamic acid benzyl amide (CABA) exhibit pleiotropic effects in cancer cells, and their exact molecular mechanism of action is under investigation. The present study is part of our systemic analysis of interactions of CABA analogs with their molecular targets. These compounds were shown to i...

journal_title：Current cancer drug targets

authors： Mielecki M,Milner-Krawczyk M,Grzelak K,Mielecki D,Krzysko KA,Lesyng B,Priebe W

更新日期：2014-01-01 00:00:00

abstract：:Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, en...

journal_title：Current cancer drug targets

authors： Matsuhashi A,Ohno T,Kimura M,Hara A,Saio M,Nagano A,Kawai G,Saitou M,Takigami I,Yamada K,Okano Y,Shimizu K

更新日期：2012-07-01 00:00:00

abstract：:Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin i...

journal_title：Current cancer drug targets

authors： Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

更新日期：2015-01-01 00:00:00

abstract：:The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2). The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a number of physiopathological proces...

journal_title：Current cancer drug targets

authors： Ulisse S,Baldini E,Sorrenti S,D'Armiento M

更新日期：2009-02-01 00:00:00

abstract：:Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recen...

journal_title：Current cancer drug targets

authors： Hardcastle J,Kurozumi K,Chiocca EA,Kaur B

更新日期：2007-03-01 00:00:00

abstract：:Actin was first identified in non-muscle cells only about three decades ago, and at about the same time, it was found that actin filaments were disrupted in the malignant transformed cells. The actin network is a rather complex, yet important structural and functional system of all eukaryotic cells. Actin filaments pr...

journal_title：Current cancer drug targets

authors： Rao J,Li N

更新日期：2004-06-01 00:00:00

abstract：:Membranous Met is classically identified with its role in cancer metastases, while nuclear Met is associated with a more invasive, aggressive and proliferative form of cancer. Full-length Met or N-terminal transmembrane domain cleaved Met can translocate into nucleus in a cell growth and pH dependent but both ligand-d...

journal_title：Current cancer drug targets

authors： Xie Y,Istayeva S,Chen Z,Tokay T,Zhumadilov Z,Wu D,Hortelano G,Zhang J

更新日期：2016-01-01 00:00:00

abstract：:Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

journal_title：Current cancer drug targets

authors： Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

更新日期：2013-09-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for ...

journal_title：Current cancer drug targets

authors： Warlick ED,Smith BD

更新日期：2007-09-01 00:00:00

abstract：:The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides its antiviral effect, its potential use in the treatment of cancer has become an important area of research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite CPEC-TP. CPEC-TP is a non c...

journal_title：Current cancer drug targets

authors： Schimmel KJ,Gelderblom H,Guchelaar HJ

更新日期：2007-08-01 00:00:00

abstract：:Several subtypes of T cells are located in a tumor environment, each of which supplies their energy using different metabolic mechanisms. Since the cancer cells require high levels of glucose, the conditions of food poverty in the tumor environment can cause inactivation of immune cells, especially the T-effector cell...

journal_title：Current cancer drug targets

authors： Iranparast S,Tayebi S,Ahmadpour F,Yousefi B

更新日期：2020-01-01 00:00:00

abstract：:The actin microfilament network is important in maintaining cell shape and function in eukaryotic cells. It has a multitude of roles in cellular processes such as cell adhesion, motility, cellular signalling, intracellular trafficking and cytokinesis. Alterations in the organisation of the cytoskeleton and changes in ...

journal_title：Current cancer drug targets

authors： Stehn JR,Schevzov G,O'Neill GM,Gunning PW

更新日期：2006-05-01 00:00:00

abstract：:Nuclear Hormone Receptors (NR) represent one of the most promising protein families in terms of therapeutic applications. These transcription factors are naturally switched on and off by small molecule hormones presenting physico-chemical properties very similar to therapeutic chemical entities. NRs represent therefor...

journal_title：Current cancer drug targets

authors： Schapira M

更新日期：2002-09-01 00:00:00

abstract：:The capacity to induce new blood vessel formation or to repair damaged vessels is an attractive idea that has, for a long time, captured the attention and imagination of researchers. Beside the identification of the pro-angiogenic growth factors and their counterpart inhibitors, the discovery of endothelial progenitor...

journal_title：Current cancer drug targets

authors： Pasquier E,Dias S

更新日期：2010-12-01 00:00:00

abstract：:Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways have revolutionized the treatment of patients with metastatic renal cell cancer (RCC). Patients with clear cell RCC often have mutations or silencing of the von Hippel Lindau gene leading to an accumulati...

journal_title：Current cancer drug targets

authors： Heng DY,Bukowski RM

更新日期：2008-12-01 00:00:00

abstract：:UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 (pp-GalNAc-T6) is a member of the N-acetyl-D-galactosamine transferase family. It catalyzes the addition of N-acetyl-D-galactosamine to proteins, often the first step in O-glycosylation of proteins. Glycosylated proteins play important role...

journal_title：Current cancer drug targets

authors： Banford S,Timson DJ

更新日期：2017-01-01 00:00:00

abstract：:There is an emerging paradigm shift in oncology that seeks to emphasize molecularly targeted approaches for cancer prevention and therapy. Chalcones (1,3-diphenyl-2-propen-1-ones), naturally-occurring compounds with widespread distribution in spices, tea, beer, fruits and vegetables, consist of open-chain flavonoids i...

journal_title：Current cancer drug targets

authors： Jandial DD,Blair CA,Zhang S,Krill LS,Zhang YB,Zi X

更新日期：2014-01-01 00:00:00

abstract：:The application of nanotechnology to biomedical research is expected to have a major impact leading to the development of new types of diagnostic and therapeutic tools. One focus in nanobiotechnology is to develop safe and efficient drug/gene delivery vehicles. Research into the rational delivery and targeting of phar...

journal_title：Current cancer drug targets

authors： Liu Y,Lou C,Yang H,Shi M,Miyoshi H

更新日期：2011-02-01 00:00:00

abstract：:Pokemon gene has crucial but versatile functions in cell differentiation, proliferation and tumorigenesis. It is a master regulator of the ARF-HDM2-p53 and Rb-E2F pathways. The facts that the expression of Pokemon is essential for tumor formation and many kinds of tumors over-express the Pokemon gene make it an attrac...

journal_title：Current cancer drug targets

authors： Tian Z,Wang H,Jia Z,Shi J,Tang J,Mao L,Liu H,Deng Y,He Y,Ruan Z,Li J,Wu Y,Ni B

更新日期：2010-12-01 00:00:00